Rehmann Capital Advisory Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.53M Buy
161,403
+6
+0% +$160 0.24% 73
2025
Q4
$4.02M Sell
161,397
-12,128
-7% -$306K 0.21% 82
2025
Q3
$4.41M Buy
173,525
+8,623
+5% +$213K 0.24% 76
2025
Q2
$4M Buy
164,902
+9,695
+6% +$226K 0.24% 77
2025
Q1
$3.93M Sell
155,207
-9,918
-6% -$260K 0.25% 81
2024
Q4
$4.38M Sell
165,125
-4,368
-3% -$118K 0.28% 70
2024
Q3
$4.93M Buy
169,493
+29
+0% +$846 0.32% 60
2024
Q2
$4.74M Buy
169,464
+31,883
+23% +$878K 0.34% 59
2024
Q1
$3.82M Buy
137,581
+3,852
+3% +$107K 0.28% 70
2023
Q4
$3.85M Buy
133,729
+10,386
+8% +$314K 0.32% 61
2023
Q3
$4.09M Sell
123,343
-5,911
-5% -$209K 0.38% 45
2023
Q2
$4.74M Buy
129,254
+18,703
+17% +$728K 0.43% 41
2023
Q1
$4.51M Sell
110,551
-257
-0.2% -$11.1K 0.42% 44
2022
Q4
$5.68M Sell
110,808
-836
-0.7% -$40.1K 0.58% 36
2022
Q3
$4.89M Sell
111,644
-840
-0.7% -$40.8K 0.54% 35
2022
Q2
$5.9M Sell
112,484
-720
-0.6% -$36.7K 0.65% 31
2022
Q1
$5.86M Sell
113,204
-6,678
-6% -$346K 0.56% 33
2021
Q4
$7.08M Sell
119,882
-4,115
-3% -$204K 0.66% 30
2021
Q3
$5.34M Buy
123,997
+3,553
+3% +$157K 0.51% 35
2021
Q2
$4.72M Buy
120,444
+772
+0.6% +$30K 0.46% 41
2021
Q1
$4.34M Sell
119,672
-937
-0.8% -$33.3K 0.44% 45
2020
Q4
$4.44M Sell
120,609
-4,774
-4% -$175K 0.5% 35
2020
Q3
$4.37M Sell
125,383
-13,776
-10% -$483K 0.55% 33
2020
Q2
$4.32M Buy
139,159
+10,499
+8% +$357K 0.59% 31
2020
Q1
$3.98M Buy
+128,660
New +$4.38M 0.65% 31
2019
Q3
$4.38M Sell
128,620
-2,051
-2% -$74.6K 0.53% 24
2019
Q2
$5.37M Buy
130,671
+4,387
+3% +$174K 0.66% 28
2019
Q1
$5.09M Sell
126,284
-3,542
-3% -$142K 0.69% 26
2018
Q4
$5.38M Sell
129,826
-2,373
-2% -$98.5K 0.81% 16
2018
Q3
$5.53M Buy
132,199
+1,854
+1% +$71.4K 0.76% 24
2018
Q2
$4.49M Buy
130,345
+8,058
+7% +$275K 0.65% 27
2018
Q1
$4.12M Buy
122,287
+4,002
+3% +$138K 0.64% 27
2017
Q4
$4.07M Sell
118,285
-2,044
-2% -$69.7K 0.69% 26
2017
Q3
$4.08M Buy
120,329
+2,693
+2% +$86.6K 0.73% 25
2017
Q2
$3.75M Sell
117,636
-9,238
-7% -$291K 0.72% 27
2017
Q1
$4.12M Buy
126,874
+6,685
+6% +$211K 0.69% 30
2016
Q4
$3.7M Buy
120,189
+3,116
+3% +$95.1K 0.68% 32
2016
Q3
$3.76M Buy
117,073
+80
+0.1% +$2.67K 0.73% 33
2016
Q2
$3.91M Buy
116,993
+4,339
+4% +$138K 0.73% 30
2016
Q1
$3.17M Sell
112,654
-20,088
-15% -$574K 0.62% 39
2015
Q4
$4.07M Buy
132,742
+1,955
+1% +$61.5K 0.85% 24
2015
Q3
$3.9M Buy
130,787
+373
+0.3% +$12K 0.88% 26
2015
Q2
$4.15M Buy
130,414
+5,682
+5% +$185K 0.95% 22
2015
Q1
$4.12M Buy
124,732
+2,398
+2% +$76.2K 0.93% 22
2014
Q4
$3.62M Sell
122,334
-3,656
-3% -$105K 0.83% 26
2014
Q3
$3.54M Sell
125,990
-1,808
-1% -$50.7K 0.84% 24
2014
Q2
$3.6M Buy
127,798
+1,038
+0.8% +$29.6K 0.86% 25
2014
Q1
$3.86M Buy
126,760
+3,719
+3% +$111K 1.04% 19
2013
Q4
$3.58M Buy
123,041
+1,718
+1% +$50K 1.08% 19
2013
Q3
$3.31M Sell
121,323
-252
-0.2% -$6.86K 1.07% 25
2013
Q2
$3.23M Buy
+121,575
New +$3.36M 1.12% 23

Other funds holding PFE

Rehmann Capital Advisory Group's PFE Position: Q1 2026 in Review

Rehmann Capital Advisory Group increased its Pfizer (PFE) stake by 0% in Q1 2026, buying an estimated $160 and bringing the position to 161,403 shares worth $4.53M. The position accounts for 0.24% of the portfolio, ranked #73.

Rehmann Capital Advisory Group first reported a position in PFE in Q2 2013 and has held it in 51 quarters since. The position peaked at $7.08M in Q4 2021. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Rehmann Capital Advisory Group held 161,403 shares of Pfizer worth $4.53M as of Q1 2026.
  • Rehmann Capital Advisory Group bought 6 Pfizer shares in Q1 2026, an estimated $160.
  • Pfizer made up 0.24% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #73 holding.
  • Rehmann Capital Advisory Group first reported a position in Pfizer in Q2 2013 and has held it in 51 quarters since.
  • Rehmann Capital Advisory Group's Pfizer position peaked at $7.08M in Q4 2021.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.